Clinical Trials

FDA Approval of ORIAHNN™ for Heavy Bleeding Due to Uterine Fibroids

FDA-Approval-of-ORIAHNN™-for-Heavy-Bleeding-Due-to-Uterine-Fibroids

Dr. Ayman Al-Hendy, MD, discusses the recent FDA approval of AbbVie’s ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), a non-surgical, oral medication option, for premenopausal women to manage heavy bleeding due to uterine fibroids. 

Frequently Asked Questions

What is the main topic discussed in this episode of Health Professional Radio?

This episode covers important developments in healthcare, including updates on Therapy. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.

How can healthcare professionals benefit from this information?

Healthcare professionals can stay informed about the latest developments in Therapy and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.

Where can I find more information about Therapy?

For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.

Dr. Ayman Al-Hendy, MD PhD FRCSC FACOG CCRP.

Dr. Ayman Al-Hendy is a gynecologist and endoscopic surgeon at the University of Illinois at Chicago (UIC) Medical Center, focused on serving women with symptomatic uterine fibroids and premature ovarian insufficiency.In addition to his current role, Dr. Al-Hendy is also a professor (tenure) and director of translational research with the UIC College of Medicine department of obstetrics and gynecology. Dr. Al-Hendy’s medical research interests focus on developing novel therapies including gene and stem cell therapy for premature ovarian insufficiency, endometriosis, and particularly uterine fibroids. He is currently researching the utility of various nutritional supplements as possible non-surgical therapy for uterine fibroids which impact negatively women health worldwide and burden resources through the high rate of hysterectomy especially in women of color. Dr. Al-Hendy graduated from Banha Faculty of Medicine, Zagazig University, Banha, Egypt in 1986. After one year of interning at Banha University Hospital, he headed to Finland to earn his Ph.D. in Molecular Medicine from the University of Turku. He then gained additional postdoctoral training in gene/cell therapy and clinical molecular genetics at McMaster University and McGill University in Canada, before completing clinical residency training in Obstetrics and Gynecology at the University of Saskatchewan and fellowship training in laparoscopic surgery at Toronto University. Dr. Al-Hendy is board-certified by the Royal College of Surgeons of Canada and The American Board of Obstetrics and Gynecology. Dr. Al-Hendy held various faculty positions at the University of Texas Medical Branch, Meharry Medical College/VanderbiltUniversity, and Medical College of Georgia, before moving to Chicago, Illinois.He has served as Chair of the National Institutes of Health (NIH) Integrative Clinical Endocrinology and Reproduction (ICER) IRG and also serves on numerous other committees with organizations such as the NIH, the American Society for Reproductive Medicine and The Society for Reproductive Investigation. Dr. Al-Hendyhas published more than 201 peer-reviewed publications in high tier peer-reviewed scientific journals, more than 260 presentations in national and international meetings and has edited five medical books.

Last updated: June 22, 2020

Medical Disclaimer

The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.